Percutaneous coronary intervention is an effective treatment for a range of
coronary syndromes. Although the success rate of the interventions has inc
reased in recent years to more than 90%, percutaneous coronary procedures a
re still associated with short-term and long-term complications. The most c
ommon angiographic short-term complication of balloon angioplasty is acute
vessel closure. Clinically, periprocedural non-e wave myocardial infarction
s are common during or immediately following the percutaneous intervention.
These complications are associated with adverse clinical prognosis. Format
ion of platelet-rich thrombi plays a major role in the pathophysiology of a
cute complications of balloon angioplasty. Potent platelet inhibition with
glycoprotein IIb-IIIa inhibitors reduces the incidence of periprocedural de
ath and myocardial infarctions, a benefit that persists at long-term follow
-up. The long-term complication of percutaneous interventions is restenosis
, which frequently requires repeated revascularization because of ischemic
pain. Most pharmacological therapies have proved ineffective for the preven
tion of restenosis. This may not be surprising, as new evidence shows that
the primary mechanism of restenosis may be arterial remodeling. Implantatio
n of coronary stents prevents lumen narrowing due to the remodeling process
, and coronary stenting significantly reduces the need for target vessel re
vascularization. Restenosis is not completely eliminated, however, and new
treatment modalities aimed at prevention of in-stent stenosis are actively
being sought.